176 related articles for article (PubMed ID: 30871484)
1. The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study.
Luo L; Wang N; Yue Y; Han Y; Lv W; Liu Z; Qiu Z; Lu H; Tang X; Zhang T; Zhao M; He Y; Shenghua H; Wang M; Li Y; Huang S; Li Y; Liu J; Tuofu Z; Routy JP; Li T
BMC Infect Dis; 2019 Mar; 19(1):257. PubMed ID: 30871484
[TBL] [Abstract][Full Text] [Related]
2. A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.
Yue Y; Wang N; Han Y; Zhu T; Xie J; Qiu Z; Song X; Li Y; Routy JP; Wang J; Li T
BMC Infect Dis; 2017 Dec; 17(1):771. PubMed ID: 29246197
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study.
Lyu T; Yue Y; Hsieh E; Han Y; Zhu T; Song X; Cao W; Lyu W; Wang J; Li T
BMC Infect Dis; 2020 Jan; 20(1):66. PubMed ID: 31964364
[TBL] [Abstract][Full Text] [Related]
4. Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.
Depincé-Berger AE; Vergnon-Miszczycha D; Girard A; Frésard A; Botelho-Nevers E; Lambert C; Del Tedesco E; Genin C; Pozzetto B; Lucht F; Roblin X; Bourlet T; Paul S
Retrovirology; 2016 Jun; 13(1):44. PubMed ID: 27363286
[TBL] [Abstract][Full Text] [Related]
5. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
[TBL] [Abstract][Full Text] [Related]
6. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
7. The CARMA Study: Early Infant Antiretroviral Therapy-Timing Impacts on Total HIV-1 DNA Quantitation 12 Years Later.
Foster C; Domínguez-Rodríguez S; Tagarro A; Gkouleli T; Heaney J; Watters S; Bamford A; Fidler K; Navarro M; De Rossi A; Palma P; Nastouli E; Rossi P; Giaquinto C; Rojo P
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):295-301. PubMed ID: 32678875
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study.
Yue Y; Li Y; Cui Y; Wang N; Huang Y; Cao W; Han Y; Zhu T; Lyu W; Xie J; Song X; Li Y; Wang T; Zhu T; Li T
BMC Infect Dis; 2021 Jun; 21(1):592. PubMed ID: 34157979
[TBL] [Abstract][Full Text] [Related]
9. Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients.
Bon I; Calza L; Musumeci G; Longo S; Bertoldi A; D'Urbano V; Gibellini D; Magistrelli E; Viale PL; Re MC
Curr HIV Res; 2017; 15(6):448-455. PubMed ID: 29210661
[TBL] [Abstract][Full Text] [Related]
10. Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV-1 infection: results from a longitudinal study in the French ANRS Primo cohort.
Novelli S; Delobel P; Bouchaud O; Avettand-Fenoel V; Fialaire P; Cabié A; Souala F; Raffi F; Catalan P; Weiss L; Meyer L; Goujard C
J Int AIDS Soc; 2020 Apr; 23(4):e25485. PubMed ID: 32333726
[TBL] [Abstract][Full Text] [Related]
11. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Bartlett JA; Miralles GD; Sevin AD; Silberman M; Pruitt SK; Ottinger J; Gryszowska V; Fiscus SA; Bucy RP;
AIDS Res Hum Retroviruses; 2002 May; 18(8):535-43. PubMed ID: 12036483
[TBL] [Abstract][Full Text] [Related]
12. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
13. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
[TBL] [Abstract][Full Text] [Related]
14. Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts.
N'takpe JB; Gabillard D; Moh R; Gardiennet E; Emieme A; Badje A; Kouame GM; Toni TD; Karcher S; Carrou JL; Ménan H; Danel C; Eholie SP; Rouzioux C; Anglaret X
EBioMedicine; 2020 Jun; 56():102815. PubMed ID: 32512517
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HIV DNA decay and immune recovery between early and chronic HIV-infected individuals 96 weeks after ART.
Qin Y; Song T; Su B; Jiao Y; Liu L; Liu Z; Zhou Y; Chen Y; Wu H
HIV Med; 2022 Mar; 23 Suppl 1():6-13. PubMed ID: 35293100
[TBL] [Abstract][Full Text] [Related]
16. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
17. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
[TBL] [Abstract][Full Text] [Related]
18. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
19. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children.
Kuhn L; Paximadis M; Da Costa Dias B; Loubser S; Strehlau R; Patel F; Shiau S; Coovadia A; Abrams EJ; Tiemessen CT
PLoS One; 2018; 13(4):e0195514. PubMed ID: 29649264
[TBL] [Abstract][Full Text] [Related]
20. HIV sequence diversity during the early phase of infection is associated with HIV DNA reductions during antiretroviral therapy.
Wang N; Li Y; Han Y; Xie J; Li T
J Med Virol; 2017 Jun; 89(6):982-988. PubMed ID: 27791274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
